Evolus vs Xeris Biopharma Holdings
Evolus and Xeris Biopharma Holdings are similar in size: $297m and $292m of revenue in their latest fiscal years. Xeris Biopharma Holdings grew faster (43.7% against 11.6%). Xeris Biopharma Holdings kept more of each dollar of sales as profit: a net margin of 0.2% against -17.4%.
| Latest fiscal year | EvolusEOLS, 2025 | Xeris Biopharma HoldingsXERS, 2025 |
|---|---|---|
| Revenue | $297m | $292m |
| Revenue growth | 11.6% | 43.7% |
| Net income | −$51.6m | $554,000 |
| Operating margin | -11.0% | 8.5% |
| Net margin | -17.4% | 0.2% |
| Return on equity | — | — |
| Free cash flow | −$45.7m | $28.6m |
| Cash | $53.8m | $111m |
| Total debt | $150m | $234m |
| Debt to equity | — | 1706.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 334 | 435 |
| Market value | $481m | $1.81bn |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | 15 (Weak) |
| Insider trades, 12 months | 0 buys, 7 sales | 0 buys, 33 sales |